Rosemont Pharmaceuticals' new parent company Perrigo has reported strong financial results for the business year ending on June 29th 2013.
The group's net sales for the 12 months came to a record $3.5 billion (2.23 billion pounds), up by 12 percent year on year, with the recent takeover of Rosemont highlighted as a key contributing factor.
“Rosemont Pharmaceuticals' new parent company Perrigo has reported strong growth over the last 12 months.“
Perrigo purchased the UK-based pharmaceutical company in February 2013 as part of a wider acquisition programme that has also seen the firm buy out Velcera and Fera Pharmaceuticals in recent months.
It also announced a definitive agreement to acquire Elan Corporation at the end of July 2013, a move that will generate further momentum for Perrigo during the coming business year.
Perrigo's chairman and chief executive officer Joseph Papa said: "This was a strong quarter where we continued to successfully drive growth across our segments, while managing costs to generate record bottom-line performance."See all the latest jobs in Pharmaceutical